Research confirms benefits of side-actuated nasal spray
Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.
The side-actuated nasal spray consists of a standard actuator coupled with a customisable shell and cap.
The research, carried out in the UK last November involving 10 regular nasal spray users, as well as six doctors (GPs and ENT specialists), showed that the side-actuated delivery device has the three advantages mentioned above.
Patients also thought a slightly longer nozzle would improve the placement of the device in the nostril when the device is actuated, and Valois will further investigate this.
The company says new user research will be carried out in the US in the coming months to confirm the results of the current study.
You may also like
Ingredients
![UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny]()
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny
Read moreThe agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
Ingredients
![UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny]()
UKHSA to investigate PFAS exposure in UK population as pharma industry faces regulatory scrutiny
The agency's new biomonitoring study will investigate PFAS exposure across the UK, providing evidence as pharmaceutical manufacturers face growing pressure around the use of forever chemicals
Pharmaceutical
![OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics]()
OGT launches four IVDR-certified CytoCell FISH probes for haematological malignancy diagnostics
The new probes advance OGT’s transition of its CytoCell portfolio from IVDD ahead of the December 2028 Class C deadline, helping laboratories maintain compliant leukaemia and myeloma testing workflows
Pharmaceutical
![Pharma’s silent sustainability risk and the supply chain fix]()
Pharma’s silent sustainability risk and the supply chain fix
Pharma is making efforts to cut emissions from its own operations: shifting to renewables, upgrading facilities, streamlining logistics²⁰. But a significant share of emissions still hides outside the company’s direct control – yet in plain sight. Now, regulators and investors are turning their focus beyond the factory gates, deep into the value chain. What they’re finding is already reshaping the rules of competitiveness, capital access, and compliance. One of pharma’s most overlooked risks is quietly moving into the foreground. And the time to act is narrowing
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![From speed to strategy: how UK life sciences should respond to China’s rise]()
From speed to strategy: how UK life sciences should respond to China’s rise
A group of biotech founders, big pharma leaders, clinical and CMC specialists, and CDMO executives gathered at a recent dinner sponsored by AsymChem to discuss a question now sitting in many boardrooms: what is China’s maturing biopharma ecosystem doing to the global industry, and how should UK companies respond?